Hanwen Wang

Loop profile ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 13

Top Venues

Science advances

bioRxiv : the preprint server for biology

CPT: pharmacometrics & systems pharmacology

Journal for immunotherapy of cancer

Johns Hopkins School of Medicine (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Johns Hopkins School of Medicine Jul 1o 2019

United States

PHD :: Biomedical Engineering

Publications

Theinmozhi Arulraj, Hanwen Wang, Leisha A Emens, Cesar A Santa-Maria, Aleksander S Popel
A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition. Science advances 9 (26) (2023)
Hanwen Wang, Theinmozhi Arulraj, Holly Kimko, Aleksander S Popel
Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition. bioRxiv : the preprint server for biology (2023)
Hanwen Wang, Theinmozhi Arulraj, Holly Kimko, Aleksander S Popel
Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition. bioRxiv : the preprint server for biology (2023)
Alberto Ippolito, Hanwen Wang, Yu Zhang, Vahideh Vakil, Hojjat Bazzazi, Aleksander S Popel
Eliciting the antitumor immune response with a conditionally activated PD-L1 targeting antibody analyzed with a quantitative systems pharmacology model. CPT: pharmacometrics & systems pharmacology (2023)
Theinmozhi Arulraj, Hanwen Wang, Leisha A Emens, Cesar A Santa-Maria, Aleksander S Popel
A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition. Science advances 9 (26) (2023)
Hanwen Wang, Theinmozhi Arulraj, Holly Kimko, Aleksander S Popel
Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition. NPJ precision oncology 7 (1) (2023)
Hanwen Wang, Theinmozhi Arulraj, Holly Kimko, Aleksander S Popel
Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition. bioRxiv : the preprint server for biology (2023)
Theinmozhi Arulraj, Hanwen Wang, Leisha A Emens, Cesar A Santa-Maria, Aleksander S Popel
A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition. Science advances 9 (26) (2023)
Hanwen Wang, Huilin Ma, Richard J Sové, Leisha A Emens, Aleksander S Popel
Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer. Journal for immunotherapy of cancer 9 (2) (2022)
Alvaro Ruiz-Martinez, Chang Gong, Hanwen Wang, Richard J Sové, Haoyang Mi, Holly Kimko, Aleksander S Popel
Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model. PLoS computational biology 18 (7) (2022)
Richard J Sové, Babita K Verma, Hanwen Wang, Won Jin Ho, Mark Yarchoan, Aleksander S Popel
Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. Journal for immunotherapy of cancer 10 (11) (2022)
Richard J Sové, Mohammad Jafarnejad, Chen Zhao, Hanwen Wang, Huilin Ma, Aleksander S Popel
QSP-IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno-Oncology Applications. CPT: pharmacometrics & systems pharmacology 9 (9) (2020)
Hanwen Wang, Oleg Milberg, Imke H Bartelink, Paolo Vicini, Bing Wang, Rajesh Narwal, Lorin Roskos, Cesar A Santa-Maria, Aleksander S Popel
In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model. Royal Society open science 6 (5) (2019)

Hanwen Wang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hanwen Wang